$3.77
5.31%
Nasdaq, Oct 05, 04:00 pm EDT. Closed.
ISIN
US5560991094
Symbol
MGNX

MacroGenics, Inc. Target price 2026 - Analyst rating & recommendation

MacroGenics, Inc. Classifications & Recommendation

Buy
64%
Hold
36%

MacroGenics, Inc. Price Target

Target Price $11.22
Price $3.77
Potential
Number of Estimates 5
5 Analysts have issued a price target MacroGenics, Inc. 2027 . The average MacroGenics, Inc. target price is $11.22. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 9 Analysts recommend MacroGenics, Inc. to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the MacroGenics, Inc. stock has an average upside potential 2027 of . Most analysts recommend the MacroGenics, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 149.50 116.68
0.31% 21.95%
EBITDA Margin -43.93% -94.41%
36.07% 114.93%
Net Margin -49.91% -70.82%
11.77% 41.89%

9 Analysts have issued a sales forecast MacroGenics, Inc. 2026 . The average MacroGenics, Inc. sales estimate is

$117m
unlock
. This is
30.41% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$174m 3.81%
unlock
, the lowest is
$57.8m 65.52%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $150m 0.31%
2026
$117m 21.95%
unlock
2027
$102m 12.83%
unlock
2028
$95.1m 6.48%
unlock
2029
$181m 90.46%
unlock
2030
$254m 40.26%
unlock
2031
$225m 11.35%
unlock
2032
$373m 65.43%
unlock
2033
$523m 40.27%
unlock

3 Analysts have issued an MacroGenics, Inc. EBITDA forecast 2026. The average MacroGenics, Inc. EBITDA estimate is

$-110m
unlock
. This is
216.01% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-113m 225.30%
unlock
, the lowest is
$-106m 203.61%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-65.7m 36.27%
2026
$-110m 67.75%
unlock
2027
$-105m 4.63%
unlock
2028
$-107m 1.94%
unlock

EBITDA Margin

2025 -43.93% 36.07%
2026
-94.41% 114.93%
unlock
2027
-103.29% 9.41%
unlock
2028
-112.59% 9.00%
unlock

9 MacroGenics, Inc. Analysts have issued a net profit forecast 2026. The average MacroGenics, Inc. net profit estimate is

$-82.6m
unlock
. This is
466.35% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-18.7m 28.24%
unlock
, the lowest is
$-162m 1,011.99%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-74.6m 11.42%
2026
$-82.6m 10.73%
unlock
2027
$-106m 28.82%
unlock
2028
$-125m 17.62%
unlock
2029
$-27.9m 77.70%
unlock
2030
$24.0m 186.03%
unlock

Net Margin

2025 -49.91% 11.77%
2026
-70.82% 41.89%
unlock
2027
-104.65% 47.77%
unlock
2028
-131.61% 25.76%
unlock
2029
-15.41% 88.29%
unlock
2030
9.45% 161.32%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -1.18 -1.30
10.28% 10.17%
P/E negative
EV/Sales 2.00

9 Analysts have issued a MacroGenics, Inc. forecast for earnings per share. The average MacroGenics, Inc. EPS is

$-1.30
unlock
. This is
490.91% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.29 31.82%
unlock
, the lowest is
$-2.55 1,059.09%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-1.18 10.28%
2026
$-1.30 10.17%
unlock
2027
$-1.67 28.46%
unlock
2028
$-1.97 17.96%
unlock
2029
$-0.44 77.66%
unlock
2030
$0.38 186.36%
unlock
2031
$-1.05 376.32%
unlock
2032
$0.22 120.95%
unlock
2033
$1.44 554.55%
unlock

P/E ratio

Current -16.27 445.55%
2026
-2.76 83.04%
unlock
2027
-2.14 22.46%
unlock
2028
-1.82 14.95%
unlock
2029
-8.16 348.35%
unlock
2030
9.49 216.30%
unlock

Based on analysts' sales estimates for 2026, the MacroGenics, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.39 439.02%
2026
2.00 43.60%
unlock
2027
2.29 14.71%
unlock
2028
2.45 6.93%
unlock
2029
1.29 47.49%
unlock
2030
0.92 28.70%
unlock
2031
1.03 12.81%
unlock
2032
0.63 39.55%
unlock
2033
0.45 28.70%
unlock

P/S ratio

Current 1.36 105.86%
2026
1.95 43.70%
unlock
2027
2.24 14.72%
unlock
2028
2.40 6.92%
unlock
2029
1.26 47.49%
unlock
2030
0.90 28.70%
unlock
2031
1.01 12.80%
unlock
2032
0.61 39.55%
unlock
2033
0.44 28.71%
unlock

Current MacroGenics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B. Riley Securities
Locked
➜
Locked
Locked Aug 17 2026
Barclays
Locked
➜
Locked
Locked Apr 20 2026
B. Riley Securities
Locked
➜
Locked
Locked Apr 10 2026
Barclays
Locked
➜
Locked
Locked Mar 10 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Nov 03 2025
Leerink Partners
Locked
➜
Locked
Locked Aug 15 2025
B. Riley Securities
Locked
➜
Locked
Locked May 20 2025
Analyst Rating Date
Locked
B. Riley Securities:
Locked
➜
Locked
Aug 17 2026
Locked
Barclays:
Locked
➜
Locked
Apr 20 2026
Locked
B. Riley Securities:
Locked
➜
Locked
Apr 10 2026
Locked
Barclays:
Locked
➜
Locked
Mar 10 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Nov 03 2025
Locked
Leerink Partners:
Locked
➜
Locked
Aug 15 2025
Locked
B. Riley Securities:
Locked
➜
Locked
May 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today